Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial sector : N::A save search
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
YS | $0.8 7.96% 7.38% 55K
|
n/a
|
| O: -7.45%
H: 0.0%
C: 0.0%
hepatitis vaccine license granted biopharma virus trial
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
PTCHF | $2.61 19.97% 4.1K
|
n/a
| Email alert
Add to watchlist
lyt-100 fibrosis trial
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
NAMS | $21.5 6.28% 5.91% 170K
|
n/a
|
| O: -6.3%
H: 2.72%
C: -2.67%
pharma disease global trial cardiovascular
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | News 0 d | $11.98 0.25% 0.25% 310K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
Published: 2024-04-04 (Crawled : 19:00) - biospace.com/
HALB | $0.0089 7.14% 42K
|
n/a
|
| O: 3.49%
H: 7.23%
C: 1.2%
contract research trial
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
Published: 2024-03-26 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.59 0.44% 0.44% 140K
|
n/a
|
| O: 1.22%
H: 3.11%
C: 2.59%
kp1077 trial therapeutics
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
Published: 2024-03-25 (Crawled : 12:00) - globenewswire.com
NAMS | $21.5 6.28% 5.91% 170K
|
n/a
|
| O: -1.03%
H: 2.61%
C: 1.91%
pharma congress trial cardiology
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
BLTE | $37.3 8.18% 7.56% 39K
|
n/a
|
| O: -1.17%
H: 2.06%
C: 1.6%
disease japan trial submission
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
Published: 2024-03-21 (Crawled : 10:00) - globenewswire.com
BNOX | $0.9201 -4.15% -4.33% 43K
|
n/a
|
| O: 2.75%
H: 3.74%
C: -6.54%
bnc210 trial results
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
Published: 2024-03-15 (Crawled : 12:30) - biospace.com/
CYBN | $0.355 -1.5% 0.0% 2.9M
|
n/a
|
| O: 1.59%
H: 7.78%
C: 5.55%
cyb004 study
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
Published: 2024-03-14 (Crawled : 12:30) - biospace.com/
CYBN | $0.355 -1.5% 0.0% 2.9M
|
n/a
|
| O: 7.14%
H: 5.53%
C: -4.67%
cyb003 fda positive meeting program design
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
Published: 2024-03-14 (Crawled : 12:00) - globenewswire.com
SXTP | $0.2452 -2.39% -2.45% 100K
|
n/a
|
| O: -0.34%
H: 4.59%
C: -6.99%
fda pharmaceuticals communication trial submission
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
Published: 2024-03-13 (Crawled : 12:30) - globenewswire.com
CMND | $1.19 -1.28% 30K
|
n/a
|
| O: -2.72%
H: 1.4%
C: -4.9%
clearance trial
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
Published: 2024-03-12 (Crawled : 12:00) - globenewswire.com
NAMS | $21.5 6.28% 5.91% 170K
|
n/a
|
| O: -0.14%
H: 14.78%
C: 12.05%
first pharma trial
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Published: 2024-03-06 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.106 -17.54% 90K
|
n/a
|
| O: 3.0%
H: 6.12%
C: 0.36%
mdna11 association update cancer research meeting trial
Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments
Published: 2024-02-28 (Crawled : 12:00) - globenewswire.com
OCS | News 0 d | $11.98 0.25% 0.25% 310K
|
n/a
|
| O: 2.54%
H: 1.39%
C: -5.8%
day trials key
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
Published: 2024-02-27 (Crawled : 09:00) - biospace.com/
PTCHF | $2.61 19.97% 4.1K
|
n/a
|
| O: -0.56%
H: 0.0%
C: -0.38%
AKLI | $0.2452 7.03% 6.57% 74K
|
|
| O: -3.85%
H: 12.67%
C: 6.92%
japan positive endeavorrx adhd trial results
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
Published: 2024-02-23 (Crawled : 12:00) - globenewswire.com
CMND | $1.19 -1.28% 30K
|
n/a
|
| O: 2.15%
H: 0.0%
C: -1.05%
cmnd-100 alcohol approval trial
OneMedNet iRWD® Draws Attention at Clinical Trials Meeting
Published: 2024-02-12 (Crawled : 18:00) - globenewswire.com
ONMD | $0.588 -3.78% -3.93% 79K
|
n/a
|
| O: 3.64%
H: 0.0%
C: -15.26%
irwd trials meeting
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
ACON | $0.2789 1.42% 1.4% 41K
|
n/a
|
| O: -3.78%
H: 2.62%
C: 0.44%
partnership update trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.